Catecholamines

FDA approves ONGENTYS® ▼ (opicapone)

Wednesday, April 29, 2020 - 8:00am

BIAL announced today that the U.S Food and Drug Administration (FDA) has approved ONGENTYS (opicapone) as an add-on treatment to levodopa/carbidopa in patients with Parkinsons disease experiencing off episodes.

Key Points: 
  • BIAL announced today that the U.S Food and Drug Administration (FDA) has approved ONGENTYS (opicapone) as an add-on treatment to levodopa/carbidopa in patients with Parkinsons disease experiencing off episodes.
  • This approval is a landmark in BIALs ongoing commitment to the quality of life of Parkinsons patients and their caregivers.
  • We look forward to working with our partner in the U.S., Neurocrine Biosciences, to make this therapy available to patients.
  • The FDA approval of opicapone is supported by data from 38 clinical studies, including two multinational Phase III clinical studies (BIPARK-1 and BIPARK-2).

Europe Epinephrine Market (2020 to 2027) - Regional Analysis and Forecasts - ResearchAndMarkets.com

Wednesday, April 22, 2020 - 4:52pm

The "Europe Epinephrine Market to 2027 - Regional Analysis and Forecasts by Product Type; Application; Distribution Channel; and Country" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Epinephrine Market to 2027 - Regional Analysis and Forecasts by Product Type; Application; Distribution Channel; and Country" report has been added to ResearchAndMarkets.com's offering.
  • The epinephrine market in Europe is anticipated to reach US$ 1,238.80 million by 2027 from US$ 680.01 million in 2019.
  • The growth of the epinephrine market is attributed primarily due to the fast growth of epinephrine technology in Europe and the growing prevalence of anaphylaxis cases in the region.
  • However, increasing R&D expenditure for growing pipeline of epinephrine is expected to have a positive impact on the growth of the epinephrine market in Europe in the coming years.

Outlook on the Attention Deficit Hyperactivity Disorder (ADHD) Market to 2026

Monday, March 9, 2020 - 9:15pm

DUBLIN, March 9, 2020 /PRNewswire/ -- The "Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)?"

Key Points: 
  • DUBLIN, March 9, 2020 /PRNewswire/ -- The "Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)?"
  • This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
  • The research estimates that in 2017, there were 177.3 million prevalent cases of attention deficit hyperactivity disorder (ADHD) in people aged 5-44 years worldwide, and forecasts that number to increase to 187.4 million prevalent cases by 2026.
  • Approved drugs in the ADHD space target dopamine, dopamine reuptake, norepinephrine (noradrenaline), norepinephrine (noradrenaline) reuptake/transporter, and the alpha 2 adrenergic receptor.

Acorda Therapeutics to Present at Cowen Annual Health Care Conference

Monday, February 24, 2020 - 12:00pm

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acordas President and Chief Executive Officer, will present at the Cowen and Company Annual Health Care Conference on Monday, March 2 at 2:50PM EST.

Key Points: 
  • Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acordas President and Chief Executive Officer, will present at the Cowen and Company Annual Health Care Conference on Monday, March 2 at 2:50PM EST.
  • INBRIJA (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinsons disease treated with carbidopa/levodopa.
  • Acorda also markets the branded AMPYRA (dalfampridine) Extended Release Tablets, 10 mg.
  • All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking.

Acorda to Present Data at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress

Wednesday, February 12, 2020 - 12:00pm

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will present new data on INBRIJA (levodopa inhalation powder) and OFF Periods at the upcoming 3rd Pan American Parkinsons Disease and Movement Disorders Congress (MDS-PAS) taking place February 14-16, 2020 in Miami, FL.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will present new data on INBRIJA (levodopa inhalation powder) and OFF Periods at the upcoming 3rd Pan American Parkinsons Disease and Movement Disorders Congress (MDS-PAS) taking place February 14-16, 2020 in Miami, FL.
  • As Parkinsons progresses, people are likely to experience OFF periods, which are characterized by the return of Parkinsons symptoms, which can occur despite underlying baseline therapy.
  • Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders.
  • INBRIJA is approved for intermittent treatment of OFF episodes in adults with Parkinsons disease treated with carbidopa/levodopa.

Acorda to Present at the 38th Annual J.P. Morgan Healthcare Conference

Wednesday, January 8, 2020 - 12:00pm

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16 at 9:30am PST / 12:30pm EST.

Key Points: 
  • Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16 at 9:30am PST / 12:30pm EST.
  • INBRIJA (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinsons disease treated with carbidopa/levodopa.
  • Acorda also markets the branded AMPYRA (dalfampridine) Extended Release Tablets, 10 mg.
  • All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking.

Global Attention Deficit Hyperactivity Disorder (ADHD) Market Spotlight 2019 Featuring Allergan, Eli Lilly, Johnson & Johnson, Takeda, Teva - ResearchAndMarkets.com

Monday, December 2, 2019 - 6:52pm

The "Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)?"

Key Points: 
  • The "Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)?"
  • The author estimates that in 2017, there were 177.3 million prevalent cases of attention deficit hyperactivity disorder (ADHD) in people aged 5-44 years worldwide, and forecasts that number to increase to 187.4 million prevalent cases by 2026.
  • Approved drugs in the ADHD space target dopamine, dopamine reuptake, norepinephrine (noradrenaline), norepinephrine (noradrenaline) reuptake/transporter, and the alpha 2 adrenergic receptor.
  • Takeda leads the industry sponsors with the highest number of clinical trials for ADHD, followed by Eli Lilly and Johnson & Johnson

Amarantus Provides Recapitalization Update to Shareholders

Monday, November 18, 2019 - 1:30pm

This plan would also allow for the settlement of the Companys outstanding liabilities and potentially provide significant upside for Amarantus shareholders.

Key Points: 
  • This plan would also allow for the settlement of the Companys outstanding liabilities and potentially provide significant upside for Amarantus shareholders.
  • Amarantus also continues to hold a 31.5% common equity position in Avant Diagnostics , which was taken private in first half of 2019.
  • At that time, Amarantus will receive additional common shares of Todos to bring Amarantus ownership in Todos to 49% prior the expected uplist capital raise.
  • We believe there is tremendous value in the Amarantus portfolio:
    Phase 2b - Parkinsons levodopa-induced dyskinesia: Next Step: Reformulation -
    Phase 2 Agitation in Alzheimers.

Kyowa Kirin Announces NOURIANZ™ (Istradefylline) Now Available in the U.S. for Treatment of Parkinson’s Disease “Off” Episodes

Monday, October 14, 2019 - 11:47pm

Kyowa Kirin, Inc. (Kyowa Kirin), an affiliate of Kyowa Kirin Co., Ltd. (TSE: 4151), announced today that NOURIANZ (istradefylline) is now available in the U.S. as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes.

Key Points: 
  • Kyowa Kirin, Inc. (Kyowa Kirin), an affiliate of Kyowa Kirin Co., Ltd. (TSE: 4151), announced today that NOURIANZ (istradefylline) is now available in the U.S. as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes.
  • To help patients with questions about access to NOURIANZ, Kyowa Kirin offers the Kyowa Kirin Cares program.
  • NOURIANZ (istradefylline) is an adenosine receptor antagonist indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes.
  • Parkinsons disease is a progressive, neurodegenerative disease characterized by motor symptoms such as tremors, rigidity, slow movement and postural instability.

Neuroscientist awarded $2.9M NIH grant to improve Parkinson's disease treatment

Wednesday, September 25, 2019 - 8:03pm

Parkinson's disease is the second most common neurodegenerative disease in the United States.

Key Points: 
  • Parkinson's disease is the second most common neurodegenerative disease in the United States.
  • Levodopa is the drug most frequently used to manage the symptoms of Parkinson's disease.
  • This potentially disabling side effect poses a major challenge in the long-term management of patients living with Parkinson's disease.
  • The NIH grant supports his study titled Neurovascular Effects of Dopamine Replacement Therapy in Parkinson's Disease.